However, in prostate cancer, upregulation of the antioxidative stress factor SRXN1 leads to radiotherapy tolerance, which can potentially be used to predict the prognosis of prostate cancer patients after radiotherapy. The gene discussed is SRXN1; the disease is Familial prostate cancer.